Depomed, Inc. (NYSE:ASRT) CEO Arthur J. Higgins acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were acquired at an average cost of $0.73 per share, for a total transaction of $18,250.00. Following the purchase, the chief executive officer now directly owns 112,879 shares of the company’s stock, valued at $82,401.67. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
NYSE:ASRT traded up $0.01 during mid-day trading on Tuesday, hitting $0.73. 1,381,058 shares of the company’s stock were exchanged, compared to its average volume of 1,133,154. Depomed, Inc. has a one year low of $0.70 and a one year high of $5.88. The business has a fifty day moving average price of $1.08 and a 200 day moving average price of $2.42.
An institutional investor recently raised its position in Depomed stock. Public Employees Retirement System of Ohio increased its holdings in shares of Depomed, Inc. (NYSE:ASRT) by 57.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,059 shares of the company’s stock after acquiring an additional 46,300 shares during the period. Public Employees Retirement System of Ohio owned approximately 0.20% of Depomed worth $438,000 at the end of the most recent reporting period.
Depomed Company Profile
Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
See Also: Put Option
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.